Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer

Por Hyman, David M., Spriggs, David R.
Publicado em 2012

Quantifying the Benefits of Genome-Driven Oncology

Por Schram, Alison M., Hyman, David M.
Publicado no Cancer Discov (2017)

Implementing Genome-Driven Oncology

Por Hyman, David M., Taylor, Barry S., Baselga, José
Publicado no Cell (2017)

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer

Por Schram, Alison M., Iasonos, Alexia, Hyman, David M.
Publicado no J Clin Oncol (2016)

Precision oncology: Charting a path forward to broader deployment of genomic profiling

Por Schram, Alison M., Berger, Michael F., Hyman, David M.
Publicado no PLoS Med (2017)

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

Por Tao, Jessica J., Schram, Alison M., Hyman, David M.
Publicado no Annu Rev Med (2017)

Primary debulking surgery for metastatic cervical adenocarcinoma: A case report

Por Davenport, Sara M., Suidan, Rudy S., Huang, James, Hyman, David M., Chi, Dennis S.
Publicado no Gynecol Oncol Rep (2015)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

Por Ji, Yan, Jin, Jin Y., Hyman, David M., Kim, Geoffrey, Suri, Ajit
Publicado no Clin Transl Sci (2018)

Clinical tumour sequencing for precision oncology: time for a universal strategy

Por Cheng, Michael L., Berger, Michael F., Hyman, David M., Solit, David B.
Publicado no Nat Rev Cancer (2018)

Towards a more precise future for oncology

Por Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M.
Publicado no Cancer Cell (2020)

(89)Zr-trastuzumab PET/CT for detection of HER2-positive metastases in patients with HER2-negative primary breast cancer

Por Ulaner, Gary A., Hyman, David M., Lyashchenko, Serge K., Lewis, Jason S., Carrasquillo, Jorge A.
Publicado no Clin Nucl Med (2017)

MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants

Por Francis, Jasmine H., Diamond, Eli L., Chi, Ping, Jaben, Korey, Hyman, David M., Abramson, David H.
Publicado no Ocul Oncol Pathol (2020)

Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program

Por Feit, Noah Z., Goldman, Debra A., Smith, Evan, Deighan, Jenny, Iasonos, Alexia, Zivanovic, Oliver, Hyman, David M.
Publicado no JAMA Oncol (2019)

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials

Por Iasonos, Alexia, Gounder, Mrinal, Spriggs, David R, Gerecitano, John F, Hyman, David M, Zohar, Sarah, O’Quigley, John
Publicado em 2012

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

Por Hyman, David M., Zhou, Qin, Arnold, Angela G., Grisham, Rachel N., Iasonos, Alexia, Kauff, Noah D., Spriggs, David
Publicado em 2011

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency

Por Cunanan, Kristen M., Gonen, Mithat, Shen, Ronglai, Hyman, David M., Riely, Gregory J., Begg, Colin B., Iasonos, Alexia
Publicado no J Clin Oncol (2017)

Automated eligibility screening and monitoring for genotype-driven precision oncology trials

Por Eubank, Michael H, Hyman, David M, Kanakamedala, Amritha D, Gardos, Stuart M, Wills, Jonathan M, Stetson, Peter D
Publicado no J Am Med Inform Assoc (2016)

Specifying the True- and False-Positive Rates in Basket Trials

Por Cunanan, Kristen M., Iasonos, Alexia, Shen, Ronglai, Hyman, David M., Riely, Gregory J., Gönen, Mithat, Begg, Colin B.
Publicado no JCO Precis Oncol (2017)

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer

Por Grisham, Rachel N., Iyer, Gopa, Sala, Evis, Zhou, Qin, Iasonos, Alexia, DeLair, Deborah, Hyman, David M., Aghajanian, Carol
Publicado no Int J Gynecol Cancer (2014)

Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma

Por Gottesdiener, Lee S., O’Connor, Shannon, Busam, Klaus J., Won, Helen, Solit, David B., Hyman, David M., Shoushtari, Alexander N.
Publicado no Clin Cancer Res (2018)